Ad5-CD/TKrep

AXP000049.1 · Oncolytic virus

Platform
adenovirus (Ad5, replication-competent, E1B-55kDa retained)
Originator
Henry Ford Health
Sponsor
Henry Ford Health

Names

NameTypeSource
Ad5-CD/TKreppreferred name, codecurator, paper

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5 (CD/TKrep)
Replication
replicating
Modifications
replication-competent Ad5 carrying a cytosine deaminase/HSV-1 thymidine kinase fusion gene
Transgenes
CD/HSV-1 TK suicide-gene fusion
Route
intratumoral
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (0)

No trial in the latest ClinicalTrials.gov snapshot names this program.

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 14612551Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.Cancer research2003name in abstract: Ad5-CD/TKrep
PMID 12208748Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer.Cancer research2002name in abstract: Ad5-CD/TKrep

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 16290236Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity.Molecular therapy : the journal of the American Society of Gene Therapy2006name in abstract: Ad5-CD/TKrep
PMID 16555996Cancer scene investigation: how a cold virus became a tumor killer.Future oncology (London, England)2005name in abstract: Ad5-CD/TKrep
PMID 12377341Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model.International journal of radiation oncology, biology, physics2002name in abstract: Ad5-CD/TKrep
PMID 10646640Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization.Human gene therapy2000name in abstract: Ad5-CD/TKrep
PMID 10933942Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse.Molecular therapy : the journal of the American Society of Gene Therapy2000name in abstract: Ad5-CD/TKrep

NIH grants

ProjectTitleOrganisationPIYearsLinked by
P01CA097012Second Generation Adenoviral Vectors for Cancer TherapyHENRY FORD HEALTH SYSTEMFREYTAG, SVEND O2004–2008name in abstract: Ad5-CD/TKrep
R21CA085551PHASE I STUDY OF COMBINED VIRAL & SUICIDE GENE THERAPIESHENRY FORD HEALTH SYSTEMFREYTAG, SVEND O1999–2000name in abstract: Ad5-CD/TKrep

Notes

First-generation Henry Ford replication-competent adenovirus carrying a cytosine deaminase/HSV-1 thymidine kinase fusion gene, given intraprostatically with 5-FC/ganciclovir and radiotherapy from 1999. Construct details not re-verified against the primary trial report.

How to cite

Ad5-CD/TKrep (AXP000049.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000049.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.